159711_CD Reed_NNP Report_NNP 103-142_CD 7_CD 3_CD 06_CD 12:05_CD Page_NNP 117_CD Reed_NNP Elsevier_NNP Annual_JJ Reports_NNS and_CC Financial_NNP Statements_NNP 2005_CD 117_CD 19_CD Reconciliations_NNS to_TO previous_JJ GAAP_NNP continued_VBD 2004_CD As_IN at_IN 31_CD December_NNP Note_NN m_NN Shareholders_NNS equity_NN under_IN previous_JJ GAAP_NNP 1,199_CD Adjustments_NNP :_: Share_NN of_IN IFRS_NNP adjustments_NNS in_IN joint_JJ ventures_NNS i_FW 439_FW Dividends_NNPS ii_FW 120_CD Shareholders_NNS equity_NN under_IN IFRS_NNP 880_CD i_FW Details_NNS of_IN the_DT IFRS_NNP adjustments_NNS made_VBD to_TO the_DT Reed_NNP Elsevier_NNP combined_VBN figures_NNS are_VBP presented_VBN in_IN note_NN 33_CD to_TO the_DT combined_VBN financial_JJ statements_NNS ._.
ii_FW Reversal_NN of_IN proposed_VBN dividends_NNS not_RB declared_VBN by_IN 31_CD December_NNP 2004_CD ._.
Under_IN IFRS_NNP the_DT carrying_VBG value_NN of_IN investments_NNS in_IN joint_JJ ventures_NNS and_CC external_JJ payables_NNS at_IN 31_CD December_NNP 2004_CD were_VBD 439m_CD and_CC 120m_CD lower_JJR respectively_RB ,_, compared_VBN to_TO the_DT figures_NNS reported_VBN under_IN previous_JJ GAAP_NNP ._.
As_IN at_IN the_DT IFRS_NNP transition_NN date_NN of_IN 1_CD January_NNP 2004_CD ,_, shareholders_NNS equity_NN was_VBD 417m_CD lower_JJR under_IN IFRS_NNP than_IN under_IN previous_JJ GAAP_NNP due_JJ to_TO the_DT share_NN of_IN IFRS_NNP adjustments_NNS in_IN joint_JJ ventures_NNS of_IN 527m_JJ and_CC the_DT reversal_NN of_IN proposed_VBN dividends_NNS of_IN 110m_CD ._.
20_CD Post_NNP balance_NN sheet_NN event_NN On_IN 14_CD February_NNP 2006_CD ,_, Reed_NNP Elseviers_NNP Group_NNP plc_NN declared_VBD a_DT dividend_NN to_TO Reed_NNP Elsevier_NNP PLC_NNP of_IN 150m_CD ._.
21_CD Principal_NN joint_JJ ventures_NNS %_NN holding_VBG Reed_NNP Elsevier_NNP Group_NNP plc_NN Incorporated_NNP and_CC operating_VBG in_IN Great_NNP Britain_NNP 10,000_CD ordinary_JJ R_NN shares_NNS 100_CD %_NN 1-3_CD Strand_NNP 10,000_CD ordinary_JJ E_NNP shares_NNS London_NNP WC2N_NNP 5JR_NNP 100,000_CD 7.5_CD %_NN cumulative_JJ preference_NN non_NN voting_VBG shares_NNS 100_CD %_NN Holding_VBG company_NN for_IN operating_VBG businesses_NNS involved_VBN in_IN science_NN &_CC medical_JJ ,_, legal_JJ ,_, educational_JJ and_CC business_NN publishing_NN Equivalent_NN to_TO a_DT 50_CD %_NN equity_NN interest_NN Elsevier_NNP Reed_NNP Finance_NNP BV_NNP Incorporated_NNP in_IN the_DT Netherlands_NNP 133_CD ordinary_JJ R_NN shares_NNS 100_CD %_NN Radarweg_NNP 29_CD 205_CD ordinary_JJ E_NNP shares_NNS 1043_CD NX_NNP Amsterdam_NNP ,_, The_DT Netherlands_NNP Holding_NNP company_NN for_IN financing_NN businesses_NNS Equivalent_NNP to_TO a_DT 39_CD %_NN equity_NN interest_NN The_DT E_NNP shares_NNS in_IN Reed_NNP Elsevier_NNP Group_NNP plc_NN and_CC Elsevier_NNP Reed_NNP Finance_NNP BV_NNP are_VBP owned_VBN by_IN Reed_NNP Elsevier_NNP NV_NNP ._.
22_CD Principal_NN subsidiary_NN %_NN holding_VBG Reed_NNP Holding_NNP BV_NNP Incorporated_NNP in_IN the_DT Netherlands_NNP 41_CD ordinary_JJ shares_NNS 100_CD %_NN Radarweg_NNP 29_CD 1043_CD NX_NNP Amsterdam_NNP ,_, The_DT Netherlands_NNP Reed_NNP Holding_NNP BV_NNP owns_VBZ 4,679,249_CD shares_NNS of_IN a_DT separate_JJ class_NN in_IN Reed_NNP Elsevier_NNP NV_NNP ,_, giving_VBG Reed_NNP Elsevier_NNP PLC_NNP a_DT 5.8_CD %_NN indirect_JJ equity_NN interest_NN in_IN Reed_NNP Elsevier_NNP NV_NNP ._.
